Bayer's ( BAY) shares rose following an announcement that the company and its partner Onyx Pharmaceuticals ( ONXX) received fast-track designation from the Food and Drug Administration for the drug Nexavar for treating skin cancer. Nexavar is already approved to treat advanced kidney cancer. Bayer's shares were up 1.7% to $47.63, but Onyx was falling 1.5% to $15.49. West Pharmaceuticals ( WST), a maker of drug-delivery devices, preannounced positive second-quarter earnings after the market closed Wednesday, sending its shares 5.7% higher to $37.06. The company says it expects to report earnings of between 60 cents and 62 cents a share Aug. 3, compared with 38 cents a year ago. West also raised its full-year guidance to $1.82 to $1.88 a share, up from its previous estimate of between $1.68 and $1.78 a share. Sales are forecast at roughly $880 million to $900 million. Baxter International's ( BAX) shares jumped 6.2% to $40.96 after the company raised its guidance for the full year. While the company earned 47 cents a share in the second quarter vs. 51 cents a year ago, it brought in sales of $2.6 billion, up 3% from last year. For the full year, Baxter expects to see sales growth of around 6% and earnings of between $2.21 and $2.25, excluding certain charges, compared with the company's previous guidance of $2.10 to $2.16. Endo Pharmaceuticals' ( ENDP) shares fell 2.5% to $30.64 despite a positive earnings report Thursday morning. The maker of painkilling drugs reported earnings of 43 cents a share compared with 37 cents last year and reaffirmed its full-year EPS guidance of $1.55 to $1.60. The company expects net sales of between $880 million and $910 million with $530 million to $540 million coming from sales of Lidoderm, a topical painkiller for patients with shingles, and $50 million to $60 million from sales of its generic version of the painkiller OxyContin.